Evolving use of seizure medications after intracerebral hemorrhage: A multicenter study

Andrew M. Naidech*, Jennifer Beaumont, Babak Jahromi, Shyam Prabhakaran, Abel Kho, Jane L. Holl

*Corresponding author for this work

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: Prophylactic medications can be a source of preventable harm, potentially affecting large numbers of patients. Few data exist about how clinicians change prescribing practices in response to new data and revisions to guidelines about preventable harm from a prophylactic medication. We sought to determine the changes in prescribing practice of seizure medications for patients with intracerebral hemorrhage (ICH) across a metropolitan area before and after new outcomes data and revised prescribing guidelines were published. Methods: We conducted an observational study using electronic medical record data from 4 academic medical centers in a large US metropolitan area. Results: A total of 3,422 patients with ICH, diagnosed between 2007 and 2012, were included. In 2009, after a publication found an association of phenytoin with higher odds of dependence or death, the use of phenytoin declined from 9.6% in 2009 to 2.2% in 2012 (p < 0.00001). Conversely, the use of levetiracetam more than doubled, from 15.1% in 2007 to 35% in 2012 (p < 0.00001). Use of levetiracetam varied among the 4 institutions from 6.7% to 29.8% (p < 0.00001). Conclusions: New data that led to revised prescribing guidelines for prophylactic seizure medications for patients with ICH were temporally associated with a significant decrease in use of the medication, potentially reducing adverse outcomes. However, a corresponding increase in the use of an alternative medication, levetiracetam, occurred despite limited knowledge about its potential effects on outcomes. Future guideline changes should anticipate and address alternatives.

Original languageEnglish (US)
Pages (from-to)52-56
Number of pages5
JournalNeurology
Volume88
Issue number1
DOIs
StatePublished - Jan 3 2017

Fingerprint

etiracetam
Cerebral Hemorrhage
Multicenter Studies
Seizures
Guidelines
Phenytoin
Electronic Health Records
Observational Studies
Publications

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Naidech, Andrew M. ; Beaumont, Jennifer ; Jahromi, Babak ; Prabhakaran, Shyam ; Kho, Abel ; Holl, Jane L. / Evolving use of seizure medications after intracerebral hemorrhage : A multicenter study. In: Neurology. 2017 ; Vol. 88, No. 1. pp. 52-56.
@article{653b24f61def4a33b8adf9c1ca5c731f,
title = "Evolving use of seizure medications after intracerebral hemorrhage: A multicenter study",
abstract = "Objective: Prophylactic medications can be a source of preventable harm, potentially affecting large numbers of patients. Few data exist about how clinicians change prescribing practices in response to new data and revisions to guidelines about preventable harm from a prophylactic medication. We sought to determine the changes in prescribing practice of seizure medications for patients with intracerebral hemorrhage (ICH) across a metropolitan area before and after new outcomes data and revised prescribing guidelines were published. Methods: We conducted an observational study using electronic medical record data from 4 academic medical centers in a large US metropolitan area. Results: A total of 3,422 patients with ICH, diagnosed between 2007 and 2012, were included. In 2009, after a publication found an association of phenytoin with higher odds of dependence or death, the use of phenytoin declined from 9.6{\%} in 2009 to 2.2{\%} in 2012 (p < 0.00001). Conversely, the use of levetiracetam more than doubled, from 15.1{\%} in 2007 to 35{\%} in 2012 (p < 0.00001). Use of levetiracetam varied among the 4 institutions from 6.7{\%} to 29.8{\%} (p < 0.00001). Conclusions: New data that led to revised prescribing guidelines for prophylactic seizure medications for patients with ICH were temporally associated with a significant decrease in use of the medication, potentially reducing adverse outcomes. However, a corresponding increase in the use of an alternative medication, levetiracetam, occurred despite limited knowledge about its potential effects on outcomes. Future guideline changes should anticipate and address alternatives.",
author = "Naidech, {Andrew M.} and Jennifer Beaumont and Babak Jahromi and Shyam Prabhakaran and Abel Kho and Holl, {Jane L.}",
year = "2017",
month = "1",
day = "3",
doi = "10.1212/WNL.0000000000003461",
language = "English (US)",
volume = "88",
pages = "52--56",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

Evolving use of seizure medications after intracerebral hemorrhage : A multicenter study. / Naidech, Andrew M.; Beaumont, Jennifer; Jahromi, Babak; Prabhakaran, Shyam; Kho, Abel; Holl, Jane L.

In: Neurology, Vol. 88, No. 1, 03.01.2017, p. 52-56.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evolving use of seizure medications after intracerebral hemorrhage

T2 - A multicenter study

AU - Naidech, Andrew M.

AU - Beaumont, Jennifer

AU - Jahromi, Babak

AU - Prabhakaran, Shyam

AU - Kho, Abel

AU - Holl, Jane L.

PY - 2017/1/3

Y1 - 2017/1/3

N2 - Objective: Prophylactic medications can be a source of preventable harm, potentially affecting large numbers of patients. Few data exist about how clinicians change prescribing practices in response to new data and revisions to guidelines about preventable harm from a prophylactic medication. We sought to determine the changes in prescribing practice of seizure medications for patients with intracerebral hemorrhage (ICH) across a metropolitan area before and after new outcomes data and revised prescribing guidelines were published. Methods: We conducted an observational study using electronic medical record data from 4 academic medical centers in a large US metropolitan area. Results: A total of 3,422 patients with ICH, diagnosed between 2007 and 2012, were included. In 2009, after a publication found an association of phenytoin with higher odds of dependence or death, the use of phenytoin declined from 9.6% in 2009 to 2.2% in 2012 (p < 0.00001). Conversely, the use of levetiracetam more than doubled, from 15.1% in 2007 to 35% in 2012 (p < 0.00001). Use of levetiracetam varied among the 4 institutions from 6.7% to 29.8% (p < 0.00001). Conclusions: New data that led to revised prescribing guidelines for prophylactic seizure medications for patients with ICH were temporally associated with a significant decrease in use of the medication, potentially reducing adverse outcomes. However, a corresponding increase in the use of an alternative medication, levetiracetam, occurred despite limited knowledge about its potential effects on outcomes. Future guideline changes should anticipate and address alternatives.

AB - Objective: Prophylactic medications can be a source of preventable harm, potentially affecting large numbers of patients. Few data exist about how clinicians change prescribing practices in response to new data and revisions to guidelines about preventable harm from a prophylactic medication. We sought to determine the changes in prescribing practice of seizure medications for patients with intracerebral hemorrhage (ICH) across a metropolitan area before and after new outcomes data and revised prescribing guidelines were published. Methods: We conducted an observational study using electronic medical record data from 4 academic medical centers in a large US metropolitan area. Results: A total of 3,422 patients with ICH, diagnosed between 2007 and 2012, were included. In 2009, after a publication found an association of phenytoin with higher odds of dependence or death, the use of phenytoin declined from 9.6% in 2009 to 2.2% in 2012 (p < 0.00001). Conversely, the use of levetiracetam more than doubled, from 15.1% in 2007 to 35% in 2012 (p < 0.00001). Use of levetiracetam varied among the 4 institutions from 6.7% to 29.8% (p < 0.00001). Conclusions: New data that led to revised prescribing guidelines for prophylactic seizure medications for patients with ICH were temporally associated with a significant decrease in use of the medication, potentially reducing adverse outcomes. However, a corresponding increase in the use of an alternative medication, levetiracetam, occurred despite limited knowledge about its potential effects on outcomes. Future guideline changes should anticipate and address alternatives.

UR - http://www.scopus.com/inward/record.url?scp=85007145632&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85007145632&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000003461

DO - 10.1212/WNL.0000000000003461

M3 - Article

C2 - 27864524

AN - SCOPUS:85007145632

VL - 88

SP - 52

EP - 56

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 1

ER -